ATXN3 and Alzheimer disease: To examine whether inhibition of the MEK/ERK pathway could manifest a general beneficial effect in other disease models, we test the effect of trametinib in an AD model expressing Aβarc [28, 29] and a polyglutamine (polyQ)-mediated SCA3 model expressing SCA3-Q84 in fly neurons [58].